Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Daré Bioscience	$3.03 -2.9%	$2.96	$2.67 ▼ $5.76	$26.82M	1.2	36,333 shs	6,489 shs
FWBI First Wave BioPharma		$3.28	$2.33 ▼ $60.00	$7.34M	1.28	212,944 shs	56,500 shs
ONCY Oncolytics Biotech	$0.61 +5.4%	$0.49	$0.33 ▼ $1.53	$52.64M	0.71	619,673 shs	755,937 shs
TPST Tempest Therapeutics	$6.61 -7.0%	$6.98	$5.35 ▼ $40.56	$24.34M	-2	174,093 shs	153,183 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Daré Bioscience	-4.00%	-4.29%	+7.96%	+8.33%	-41.04%
FWBI First Wave BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
ONCY Oncolytics Biotech	+0.75%	+73.35%	+8.03%	-7.70%	-43.99%
TPST Tempest Therapeutics	-4.82%	-10.45%	+4.71%	-34.86%	-82.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Daré Bioscience	1.7024 of 5 stars	3.3	3.0	0.0	0.0	2.9	0.0	0.0
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	1.4768 of 5 stars	3.4	2.0	0.0	0.0	2.5	0.0	0.0
TPST Tempest Therapeutics	2.5778 of 5 stars	3.3	5.0	0.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Daré Bioscience	2.50	Moderate Buy	$12.00	296.04% Upside
FWBI First Wave BioPharma	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	612.72% Upside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	353.86% Upside

Current Analyst Ratings Breakdown

Latest FWBI, TPST, ONCY, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Daré Bioscience	$25.91K	1,034.99	N/A	N/A	($0.61) per share	-4.97
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	$6.54 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Daré Bioscience	-$30.16M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-18.98%	8/11/2025 (Estimated)
FWBI First Wave BioPharma	-$15.80M	N/A	0.00	N/A	N/A	N/A	-102.83%	-22.74%	N/A
ONCY Oncolytics Biotech	-$20.56M	-$0.29	N/A	N/A	N/A	N/A	-141.15%	-84.73%	7/30/2025 (Estimated)
TPST Tempest Therapeutics	-$29.49M	-$17.98	N/A	N/A	N/A	N/A	-187.44%	-82.61%	8/6/2025 (Estimated)

Latest FWBI, TPST, ONCY, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/13/2025	Q1 2025	TPST Tempest Therapeutics	-$3.71	-$3.16	+$0.55	-$3.16	N/A	N/A
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Daré Bioscience	N/A	1.14	1.14
FWBI First Wave BioPharma	0.40	1.21	1.58
ONCY Oncolytics Biotech	N/A	2.99	2.99
TPST Tempest Therapeutics	N/A	1.69	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Daré Bioscience	6.70%
FWBI First Wave BioPharma	12.30%
ONCY Oncolytics Biotech	6.82%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
DARE Daré Bioscience	4.00%
FWBI First Wave BioPharma	0.49%
ONCY Oncolytics Biotech	0.10%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
FWBI First Wave BioPharma	9	2.48 million	2.46 million	Not Optionable
ONCY Oncolytics Biotech	30	86.58 million	85.42 million	Not Optionable
TPST Tempest Therapeutics	20	3.68 million	41.59 million	Optionable

FWBI, TPST, ONCY, and DARE Headlines

Recent News About These Companies

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11 at 3:54 PM | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11 at 8:27 AM | quiverquant.com

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11 at 8:00 AM | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025 | globenewswire.com

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

April 25, 2025 | empr.com

Cash-strapped Bay Area biotech company lays off all but 5 employees

April 24, 2025 | msn.com

Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495

April 23, 2025 | nasdaq.com

Tempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous Polyposis

April 23, 2025 | nasdaq.com

Tempest Therapeutics

April 22, 2025 | thepharmaletter.com

Tempest Therapeutics stock rises on FDA Orphan Drug Designation

April 21, 2025 | in.investing.com

Tempest lays off 80% of workforce to ride out cash crunch

April 21, 2025 | fiercebiotech.com

Tempest Therapeutics announces FDA granted ODD to TPST-1495

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FWBI, TPST, ONCY, and DARE Company Descriptions

Daré Bioscience NASDAQ:DARE

$3.03 -0.09 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$3.06 +0.04 (+1.16%)

As of 04:04 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

First Wave BioPharma NASDAQ:FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Oncolytics Biotech NASDAQ:ONCY

$0.61 +0.03 (+5.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 -0.04 (-6.41%)

As of 04:39 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Tempest Therapeutics NASDAQ:TPST

$6.61 -0.50 (-7.03%)

Closing price 04:00 PM Eastern

Extended Trading

$6.72 +0.11 (+1.66%)

As of 04:35 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time